<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Zika virus envelope nanoparticle antibodies protect mice without risk of" exact="disease" post="enhancement ShuklaRahula1ShanmugamRajgokul K.a1RamasamyViswanathanaAroraUpasanaa2BatraGauravbAcklinJoshua A.cKrammerFloriancLimJean K.cSwaminathanSathyamangalamswami@icgeb.res.ina�?�KhannaNavinnavin@icgeb.res.inab�?��?�[a], [b], [c], �?�Corresponding author."/>
 <result pre="protect against ZIKV but must also not sensitise vaccinees to" exact="severe dengue." post="Methods The N-terminal 80% of ZIKV envelope protein (80E)"/>
 <result pre="Stat2−/− mice, respectively. Its capacity to enhance DENV and ZIKV" exact="infection" post="was assessed in AG129 and C57BL/6 Stat2−/− mice, respectively."/>
 <result pre="before this study Currently there is no vaccine to prevent" exact="infection" post="by Zika virus, a mosquito-borne flavivirus closely related to"/>
 <result pre="dengue virus antibodies may have helped enhance the severity of" exact="Zika virus disease" post="in these epidemics. Human sera from dengue patients can"/>
 <result pre="antibodies may have helped enhance the severity of Zika virus" exact="disease" post="in these epidemics. Human sera from dengue patients can"/>
 <result pre="these epidemics. Human sera from dengue patients can enhance Zika" exact="virus infection" post="both in cultured cells and mice. Likewise, sera from"/>
 <result pre="epidemics. Human sera from dengue patients can enhance Zika virus" exact="infection" post="both in cultured cells and mice. Likewise, sera from"/>
 <result pre="mice. Likewise, sera from Zika virus-infected patients can enhance dengue" exact="virus infection" post="of cells in culture. The cross-reactivity underlying the infection"/>
 <result pre="Likewise, sera from Zika virus-infected patients can enhance dengue virus" exact="infection" post="of cells in culture. The cross-reactivity underlying the infection"/>
 <result pre="virus infection of cells in culture. The cross-reactivity underlying the" exact="infection" post="enhancement phenomenon is linked to antibodies elicited by the"/>
 <result pre="to create a recombinant nanoparticle vaccine for Zika in the" exact="absence of" post="the pre-membrane protein implicated in the induction of cross-reactive,"/>
 <result pre="challenge, does not cause enhancement of either dengue or Zika" exact="virus infection" post="in mice. Implications of all the available evidence None"/>
 <result pre="does not cause enhancement of either dengue or Zika virus" exact="infection" post="in mice. Implications of all the available evidence None"/>
 <result pre="ideal Zika vaccine must induce antibodies which can prevent Zika" exact="virus infection," post="while at the same time being incapable of enhancing"/>
 <result pre="of eventual dengue infection. As the incidence of new Zika" exact="infections" post="is almost absent at the current time, clinical efficacy"/>
 <result pre="candidates is not possible. Active pre-clinical development of Zika virus-blocking," exact="infection" post="enhancement-free vaccine candidates will ensure their availability for efficacy"/>
 <result pre="is a mosquito-borne flavivirus, phylogenetically related to West Nile virus," exact="Yellow fever" post="virus, Japanese encephalitis virus, tick-borne encephalitis virus and dengue"/>
 <result pre="flavivirus, phylogenetically related to West Nile virus, Yellow fever virus," exact="Japanese encephalitis" post="virus, tick-borne encephalitis virus and dengue viruses (DENV) [1]."/>
 <result pre="phylogenetically related to West Nile virus, Yellow fever virus, Japanese" exact="encephalitis" post="virus, tick-borne encephalitis virus and dengue viruses (DENV) [1]."/>
 <result pre="to West Nile virus, Yellow fever virus, Japanese encephalitis virus," exact="tick-borne encephalitis" post="virus and dengue viruses (DENV) [1]. It has a"/>
 <result pre="West Nile virus, Yellow fever virus, Japanese encephalitis virus, tick-borne" exact="encephalitis" post="virus and dengue viruses (DENV) [1]. It has a"/>
 <result pre="been historically associated with mild and self-limiting fever, akin to" exact="dengue fever" post="[3,4]. ZIKV may also be transmitted between humans sexually"/>
 <result pre="and the Americas [3,8,9]. More severe clinical manifestations of ZIKV" exact="infection" post="became apparent in the Brazilian outbreaks during 2015. Exposure"/>
 <result pre="severe clinical manifestations of ZIKV infection became apparent in the" exact="Brazilian" post="outbreaks during 2015. Exposure of fetuses to ZIKV in"/>
 <result pre="of pregnancy has been linked to neurodevelopmental malfunction resulting in" exact="congenital" post="birth defects including microcephaly [7,[10], [11], [12]]. On the"/>
 <result pre="linked to neurodevelopmental malfunction resulting in congenital birth defects including" exact="microcephaly" post="[7,[10], [11], [12]]. On the other hand, ZIKV infection"/>
 <result pre="including microcephaly [7,[10], [11], [12]]. On the other hand, ZIKV" exact="infection" post="in adults appears to lead to an autoimmune disease"/>
 <result pre="hand, ZIKV infection in adults appears to lead to an" exact="autoimmune" post="disease known as Guillain Barré syndrome [13]. These neurological"/>
 <result pre="ZIKV infection in adults appears to lead to an autoimmune" exact="disease" post="known as Guillain Barré syndrome [13]. These neurological abnormalities"/>
 <result pre="to lead to an autoimmune disease known as Guillain Barré" exact="syndrome" post="[13]. These neurological abnormalities have been linked to the"/>
 <result pre="of ZIKV to infect human neural progenitor cells [14]. ZIKV" exact="infections" post="are beginning to be reported in India. It is"/>
 <result pre="considered suitable for ZIKV transmission [15]. The incidence of ZIKV" exact="infections" post="has almost totally vanished as of now and it"/>
 <result pre="pastoris, and the E. coli origin of replication (Ori), for" exact="bacterial" post="propagation. (d) Analysis of localisation of recombinant ZIKV-80E protein"/>
 <result pre="beads and separated into supernatant (S) and pellet (P) fractions." exact="Total" post="(T) extract prepared from an equivalent aliquot of the"/>
 <result pre="(lanes 1–4) and 2 (lanes 5–8) shown in panel ‘e’." exact="Protein" post="markers were analysed in lane ‘M’. Their sizes (in"/>
 <result pre="for ADE of ZIKV infection, resulting in more severe clinical" exact="disease" post="[24,25]. The corollary that ZIKV-induced antibodies may possess the"/>
 <result pre="ADE of DENV infection, which in turn could lead to" exact="severe dengue" post="disease, poses a significant hurdle to ZIKV vaccine development."/>
 <result pre="of DENV infection, which in turn could lead to severe" exact="dengue disease," post="poses a significant hurdle to ZIKV vaccine development. Numerous"/>
 <result pre="[17,26,27]. Several of these, including an mRNA-based vaccine, a recombinant" exact="measles" post="virus-vectored vaccine and several plasmid DNA-based and inactivated ZIKV"/>
 <result pre="the immune system, and inherently safe, as they lack the" exact="infectious" post="viral genome. We recently found that the amino-terminal 80%"/>
 <result pre="immune system, and inherently safe, as they lack the infectious" exact="viral" post="genome. We recently found that the amino-terminal 80% of"/>
 <result pre="Pichia pastoris can self-assemble into 20–50 nm particles, in the" exact="absence of" post="prM [43], [44], [45], [46]. Though the reports call"/>
 <result pre="P. pastoris host, could also self-assemble into NPs, in the" exact="absence of" post="prM. We also tested if these putative NPs would"/>
 <result pre="whether such ZIKV-80E NP-induced antibodies would enhance DENV and ZIKV" exact="infections" post="in vivo. This paper describes our efforts to create"/>
 <result pre="Engineering and Biotechnology (ICGEB), New Delhi (ICGEB/IAEC/08/2016/RGP-14 and ICGEB/IAEC/02042019/RGP-2). DENV" exact="type 2" post="(DENV-2) challenge experiments using AG129 mice were carried out"/>
 <result pre="integrative, expression plasmid, pPICZ-A, were from Invitrogen Life Technologies (Thermo" exact="Fisher" post="Scientific), Carlsbad, CA, USA. E. coli plasmids for expression"/>
 <result pre="CVCL_0059), and K562 cells (ATCC Cat# CCL-243; RRID: CVCL_0004), from" exact="American" post="Type Culture Collection (Manassas, VA, USA), were cultured in"/>
 <result pre="and the presence of the recombinant protein analysed, in the" exact="total" post="extract (T), supernatant (S), and urea-solubilised pellet (P) fractions,"/>
 <result pre="route. Sera were collected on day 38 for determination of" exact="total" post="antibody titres by indirect ELISA and nAb titres by"/>
 <result pre="BALB/c mice (n = 5) were immunised (i.m.) with ∼105" exact="Infectious" post="Units (IU) of purified DENV-2 (S16803), twice on days"/>
 <result pre="are provided in Methods S2 (Supplementary File). 2.8 Determination of" exact="total" post="antibody titres in immune sera Total antibody titres in"/>
 <result pre="File). 2.8 Determination of total antibody titres in immune sera" exact="Total" post="antibody titres in immune sera were estimated by indirect"/>
 <result pre="with reference to the number of ZIKV-infected cells in the" exact="absence of" post="serum taken as 100%. ZIKV nAb titres were also"/>
 <result pre="as 100%. ZIKV nAb titres were also determined using single-round" exact="infectious" post="ZIKV RVPs, encoding Renilla luciferase reporter, as described earlier"/>
 <result pre="to the luciferase activity expressed by ZIKV RVP in the" exact="absence of" post="immune serum, taken as 100%. In some ZIKV RVP"/>
 <result pre="reference to the number of cells infected by DENV in" exact="absence of" post="immune serum, taken as 100%. 2.10 Determination of protective"/>
 <result pre="for its ability to mediate ADE of a non-pathogenic ZIKV" exact="infection" post="in vivo, using C57BL/6 Stat2−/− mouse model [24,50] (Methods"/>
 <result pre="1a and b). These sequences were derived from the ZikaSPH2015" exact="Brazilian" post="strain. ZikaSPH2015 E protein displays at least 99% sequence"/>
 <result pre="at least 96% sequence identity with the E proteins of" exact="African" post="ZIKV strains and 55–57% sequence identity with respect to"/>
 <result pre="also exclusively present in the insoluble P fraction of the" exact="total" post="lysate. Therefore, we purified it under denaturing conditions. Recombinant"/>
 <result pre="of ZIKV-80E NPs (the scale is shown on the left" exact="lower" post="edge). 3.2 ZIKV-80E protein self-assembles into NPs which preserve"/>
 <result pre="P. pastoris host system self-assemble into unique NPs, in the" exact="absence of" post="the cognate prM proteins [43], [44], [45], [46]. Therefore,"/>
 <result pre="we examined if ZIKV-80E expressed in P. pastoris in the" exact="absence of" post="prM also would possess the ability to form higher"/>
 <result pre="pastoris host system does self-assemble into discrete NPs, in the" exact="absence of" post="any prM. The capacity of recombinant ZIKV-80E protein to"/>
 <result pre="is quite complex in that it is comprised of several" exact="secondary" post="structure elements that include the A-strand, the B–C loop,"/>
 <result pre="but not as potent as ZV-67), which recognises another distinct" exact="secondary" post="structural element, the C–C’ loop, suggest subtle difference(s) between"/>
 <result pre="NP-cross-reactive end-point titres were more than an order of magnitude" exact="lower" post="than those against ZIKV E NPs (Supplementary File, Fig."/>
 <result pre="solid grey curve; PRVABC59: dashed grey curve). Data depict ZIKV" exact="infection" post="(%) as a function of serum dilution. The horizontal"/>
 <result pre="ZIKV infection (%) as a function of serum dilution. The" exact="horizontal" post="dashed line denotes 50% ZIKV infection. Next, we carried"/>
 <result pre="virtually indiscernible for DENV serotypes 1 and 3 and significantly" exact="lower" post="(p&amp;lt;0.0001) for the remaining serotypes, compared to ZIKV EDIII-specific"/>
 <result pre="outside and infect susceptible cells once, but do not produce" exact="infectious" post="progeny, as they lack the structural genes. Instead they"/>
 <result pre="determined using ZIKV RVPs. The data are represented as percent" exact="infection" post="(in terms of Renilla luciferase activity of ZIKV RVPs)"/>
 <result pre="immune serum dilution, with luciferase activity of ZIKV RVP in" exact="absence of" post="immune serum taken to represent 100% infection. Virus neutralisation"/>
 <result pre="parallel is shown by the solid grey curve. The dashed" exact="horizontal" post="line in both panels denotes 50% infection based on"/>
 <result pre="curve. The dashed horizontal line in both panels denotes 50%" exact="infection" post="based on ZIKV RVP luciferase activity. Can this ZIKV-specific"/>
 <result pre="generation of memory B cells as a result of the" exact="primary" post="immunisation. Specific T-cell stimulation studies may shed further light"/>
 <result pre="we analysed immune sera from the memory recall experiment above." exact="Total" post="EDIII-specific antibody titres in the day 170 immune serum,"/>
 <result pre="that in this experiment, MBP-depleted serum was omitted as its" exact="total" post="IgG titres did not change significantly after MBP depletion,"/>
 <result pre="panel ‘a’ (dotted curve). The data are represented as percent" exact="infection" post="(in terms of Renilla luciferase activity of ZIKV RVPs)"/>
 <result pre="immune serum dilution, with luciferase activity of ZIKV RVP in" exact="absence of" post="immune serum taken to represent 100% infection. The dashed"/>
 <result pre="of immune serum taken to represent 100% infection. The dashed" exact="horizontal" post="line denotes 50% inhibition of ZIKV reporter activity. 3.4"/>
 <result pre="ZIKV infectivity in vitro be effective in countering lethal ZIKV" exact="infection" post="in vivo? To address this question, we used C57BL/6"/>
 <result pre="lose body weight starting on day 3, become morbid, show" exact="limited" post="movement and completely succumb by the end of the"/>
 <result pre="mean ZIKV RNA levels in the groups which received 10-fold" exact="lower" post="amount of anti-ZIKV-80E NP antiserum [α-ZIKV-80E (20 µl) group,"/>
 <result pre="for the criteria listed for up to 15 days. (b)" exact="Blood" post="plasma viral RNA levels (ZIKV genome copies/ml plasma) in"/>
 <result pre="criteria listed for up to 15 days. (b) Blood plasma" exact="viral" post="RNA levels (ZIKV genome copies/ml plasma) in ZIKV MR766-challenged"/>
 <result pre="As expected, pre-incubation of DENVs with mAb 4G2, followed by" exact="infection" post="onto K562 cells, resulted in ADE of infection for"/>
 <result pre="followed by infection onto K562 cells, resulted in ADE of" exact="infection" post="for each of the four DENV serotypes. This was"/>
 <result pre="four DENV serotypes. This was evident from the typical bell-shaped" exact="infection" post="profiles, as a function of mAb 4G2 concentration during"/>
 <result pre="range tested for the polyclonal anti-DENV-2 antiserum, no ADE of" exact="infection" post="was discernible in K562 cells for any of the"/>
 <result pre="by flow cytometry using mAb 2H2-Alexa 488 conjugate. Data depict" exact="infection" post="profiles of DENV-1 (magenta), DENV-2 (green), DENV-3 (blue) or"/>
 <result pre="experiment in AG129 mice (abbreviations: IC: immune complex; FIU: FACS" exact="infectious" post="unit). (f) Kaplan–Meier survival curves for groups (n ="/>
 <result pre="star symbol). That anti-ZIKV-80E NP antibodies did not enhance DENV" exact="infection" post="is notable. How relevant are the data on ADE"/>
 <result pre="(Fig. 7e). This mouse can sustain a sub-lethal DENV-2 S221" exact="infection" post="without succumbing to it. But in the presence of"/>
 <result pre="But in the presence of an enhancing antibody, the sub-lethal" exact="infection" post="escalates to a lethal infection [49,54,57,58]. When these mice"/>
 <result pre="an enhancing antibody, the sub-lethal infection escalates to a lethal" exact="infection" post="[49,54,57,58]. When these mice were injected with immune complexes"/>
 <result pre="induced by ZIKV-80E NPs could potentially cause enhancement of ZIKV" exact="infection" post="in vivo, under conditions of sub-neutralising nAb levels. To"/>
 <result pre="C57BL/6 Stat2−/− mouse model, in conjunction with ZIKV strain PRVABC59." exact="Infection" post="with this ZIKV strain, which is least pathogenic to"/>
 <result pre="relevance of the FcR pathway, in the context of ZIKV" exact="infection" post="is unknown at this time. Fig. 8 Evaluation of"/>
 <result pre="work, we found that DENV-80E proteins, when expressed in the" exact="absence of" post="the prM proteins, in P. pastoris, exhibit the capacity"/>
 <result pre="that the particle formation in these instances occurs in the" exact="absence of" post="prM. The mechanism of assembly of P. pastoris-expressed ZIKV-80E"/>
 <result pre="purification of the recombinant ZIKV-80E under denaturing conditions. As the" exact="primary" post="purpose of this work was to assess if P."/>
 <result pre="FLE-specific antibodies have been reported to mediate ADE of DENV-2" exact="infection" post="in vivo using the AG129 mouse model [32]. Consistent"/>
 <result pre="to display EDIII, the ZIKV-80E NPs elicited predominantly ZIKV EDIII-specific" exact="total" post="antibody titres (log10 serum titres, &amp;gt;5). Importantly, the ZIKV-80E"/>
 <result pre="the light of recent findings that ZIKV EDIII displayed on" exact="Hepatitis" post="B surface antigen VLP platform elicited much lower nAb"/>
 <result pre="displayed on Hepatitis B surface antigen VLP platform elicited much" exact="lower" post="nAb titres, by comparison [48]. Many ZIKV vaccine development"/>
 <result pre="ZIKV MR766=461), passive-transferred per mouse, undergoes ∼12-fold dilution (assuming a" exact="total" post="blood volume of ∼2.5 ml/mouse), one may argue that"/>
 <result pre="assessed protective efficacy following challenge with Brazilian, Puerto Rican or" exact="African" post="ZIKV strains, in terms of either suppression of viremia"/>
 <result pre="help meaningful comparison of different vaccine candidates. As severe ZIKV" exact="infection" post="is associated with fetal abnormalities, it would be relevant"/>
 <result pre="mAbs specific to EDI/II from ZIKV-infected patients can enhance DENV-2" exact="infection" post="both in vitro and in vivo[32]. Thus, a potential"/>
 <result pre="of DENV infection, especially in the current situation when DENV" exact="infections" post="continue to occur in the absence of new ZIKV"/>
 <result pre="current situation when DENV infections continue to occur in the" exact="absence of" post="new ZIKV infections. Our data showed that ZIKV-80E NPs"/>
 <result pre="of anti-ZIKV-80E NP antisera to escalate a sub-lethal DENV-2 S221" exact="infection" post="of AG129 mice into a lethal infection. It is"/>
 <result pre="limitations to the work presented in this study. As the" exact="primary" post="purpose was to evaluate the feasibility of ZIKV-80E as"/>
 <result pre="shortcoming is that this study has carried out only a" exact="limited" post="biophysical characterisation of the ZIKV-80E NPs. A more comprehensive"/>
 <result pre="while extrapolating vaccine efficacy in the mouse model to ZIKV" exact="infection" post="in humans. That P. pastoris expressed ZIKV-80E can self-assemble"/>
 <result pre="into immunogenic NPs is associated with some desirable features. The" exact="absence of" post="prM eliminates any potential safety concern relating to ADE"/>
 <result pre="of both ZIKV as well as DENVs. Further, in the" exact="absence of" post="prM, the E protein self-assembly process appears to favour"/>
 <result pre="ICGEB: RS, VR, SS, NK; Grant from NIAID: JKL, FK;" exact="Patent" post="201911014359 pending: RS, RKS, VR, UA, SS, NK. References"/>
 <result pre="sequencing of Zika virus from amniotic fluid of fetuses with" exact="microcephaly" post="in Brazil: a case studyLancet Infect Dis16201665366026897108 13Cao-LormeauV.M.BlakeA.MonsS.Guillain-Barre syndrome"/>
 <result pre="with microcephaly in Brazil: a case studyLancet Infect Dis16201665366026897108 13Cao-LormeauV.M.BlakeA.MonsS.Guillain-Barre" exact="syndrome" post="outbreak associated with Zika virus infection in French Polynesia:"/>
 <result pre="case studyLancet Infect Dis16201665366026897108 13Cao-LormeauV.M.BlakeA.MonsS.Guillain-Barre syndrome outbreak associated with Zika" exact="virus infection" post="in French Polynesia: a case-control studyLancet38720161531153926948433 14TangH.HammackC.OgdenS.C.Zika virus infects"/>
 <result pre="studyLancet Infect Dis16201665366026897108 13Cao-LormeauV.M.BlakeA.MonsS.Guillain-Barre syndrome outbreak associated with Zika virus" exact="infection" post="in French Polynesia: a case-control studyLancet38720161531153926948433 14TangH.HammackC.OgdenS.C.Zika virus infects"/>
 <result pre="in French Polynesia: a case-control studyLancet38720161531153926948433 14TangH.HammackC.OgdenS.C.Zika virus infects human" exact="cortical" post="neural progenitors and attenuates their growthCell Stem Cell18201658759026952870 15MessinaJ.P.KraemerM.U.G.BradyO.J.Mapping"/>
 <result pre="epidemic in Latin AmericaScience353201635335427417493 17AbbinkP.StephensonK.E.BarouchD.HZika virus vaccinesNature162018594600 18collab: The Lancet" exact="Infectious" post="Diseases Editorial BoardVaccine against Zika virus must remain a"/>
 <result pre="in Latin AmericaScience353201635335427417493 17AbbinkP.StephensonK.E.BarouchD.HZika virus vaccinesNature162018594600 18collab: The Lancet Infectious" exact="Diseases" post="Editorial BoardVaccine against Zika virus must remain a priorityLancet"/>
 <result pre="outbreaks in the AmericasAm J Trop Med Hyg87201258459323042846 22CastanhaP.M.S.CordeiroM.T.MartelliC.M.T.SouzaW.V.MarquesE.T.A.JrBragaCForce of" exact="infection" post="of dengue serotypes in a population-based study in northeast"/>
 <result pre="in northeast BrazilEpidemiol Infect14120131080108822800513 23BragaC.LunaC.F.MartelliC.M.Seroprevalence and risk factors for dengue" exact="infection" post="in socio-economically distinct areas of Recife, BrazilActa Trop113201023424019896921 24BardinaS.V.BunducP.TripathiS.Enhancement"/>
 <result pre="preexisting antiflavivirus immunityScience356201717518028360135 25DejnirattisaiW.SupasaP.WongwiwatW.Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of" exact="infection" post="with Zika virusNat Immunol1720161102110827339099 26PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJDevelopment of vaccines against Zika"/>
 <result pre="resolution cryo-EM structure of Zika virusScience352201646747027033547 36KostyuchenkoV.A.LimE.X.Y.ZhangS.Structure of the thermally" exact="stable" post="Zika virusNature533201642542827093288 37YuanL.HuangX.Y.LiuZ.Y.A single mutation in the prM protein"/>
 <result pre="vaccine has implications for flavivirus vaccine designJ Virol912017e01181–17 43ManiS.TripathiL.RautR.Pichia pastoris-expressed" exact="Dengue" post="2 envelope forms virus-like particles without pre-membrane protein and"/>
 <result pre="protein and induces high titer neutralizing antibodiesPLoS One82013e6459523717637 44TripathiL.ManiS.RautR.Pichia pastoris-expressed" exact="Dengue" post="3 envelope-based virus-like particles elicit predominantly domain III-focused high"/>
 <result pre="titer neutralizing antibodiesFront Microbiol62015100526441930 45PoddarA.RamasamyV.ShuklaR.Virus-like particles derived from Pichia pastoris-expressed" exact="Dengue" post="virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain"/>
 <result pre="antibodiesFront Microbiol62015100526441930 45PoddarA.RamasamyV.ShuklaR.Virus-like particles derived from Pichia pastoris-expressed Dengue virus" exact="type 1" post="glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodiesBMC Biotechnol1620165027301568"/>
 <result pre="glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodiesBMC Biotechnol1620165027301568 46KhetarpalN.ShuklaR.RajpootR.K.Recombinant" exact="Dengue" post="virus 4 envelope glycoprotein virus-like particles derived from Pichia"/>
 <result pre="Hyg96201712613427821688 47SapparapuG.FernandezE.KoseN.Neutralizing human antibodies prevent Zika virus replication and fetal" exact="disease" post="in miceNature540201644344727819683 48ShanmugamR.K.RamasamyV.ShuklaR.AroraU.SwaminathanS.KhannaNPichia pastoris-expressed Zika virus envelope domain III"/>
 <result pre="Clin Microbiol4520073777378017804661 52BatraG.GurramkondaC.NemaniS.K.JainS.K.SwaminathanS.KhannaNOptimization of conditions for secretion of dengue virus" exact="type 2" post="envelope domain III using Pichia pastorisJ Biosci Bioengg1102010408414 53HenchalE.A.GentryM.K.McCownJ.M.BrandtW.EDengue"/>
 <result pre="monoclonal antibodies by indirect immunofluorescenceAm J Trop Med Hyg31982830836 54WatanabeS.K.ChanW.K.WangJ.RivinoJ.L.LokS.M.VasudevanS.GDengue" exact="virus infection" post="with highly neutralizing levels of cross-reactive antibodies causes acute"/>
 <result pre="antibodies by indirect immunofluorescenceAm J Trop Med Hyg31982830836 54WatanabeS.K.ChanW.K.WangJ.RivinoJ.L.LokS.M.VasudevanS.GDengue virus" exact="infection" post="with highly neutralizing levels of cross-reactive antibodies causes acute"/>
 <result pre="virus infection with highly neutralizing levels of cross-reactive antibodies causes" exact="acute" post="lethal small intestinal pathology without a high level of"/>
 <result pre="and enhancement of West Nile virus infectionCell Host Microbe1200713514518005691 60FowlerA.M.TangW.W.YoungM.P.Maternally" exact="acquired" post="Zika antibodies enhance Dengue disease severity in miceCell Host"/>
 <result pre="Nile virus infectionCell Host Microbe1200713514518005691 60FowlerA.M.TangW.W.YoungM.P.Maternally acquired Zika antibodies enhance" exact="Dengue" post="disease severity in miceCell Host Microbe24201874375030439343 61GeorgeJ.ValiantW.G.MattapallilM.J.Prior exposure to"/>
 <result pre="virus infectionCell Host Microbe1200713514518005691 60FowlerA.M.TangW.W.YoungM.P.Maternally acquired Zika antibodies enhance Dengue" exact="disease" post="severity in miceCell Host Microbe24201874375030439343 61GeorgeJ.ValiantW.G.MattapallilM.J.Prior exposure to Zika"/>
 <result pre="4: expression, membrane association, secretion and particle formation in the" exact="absence of" post="precursor membrane proteinPLoS One92014e100641 63EspinosaD.MendyJ.ManayaniD.Passive transfer of immune sera"/>
</results>
